For personal use only

## ASX Announcement

# Imugene Completes $11.1 Million Placement to Advance azer-cel Following Positive Cohort 3 Clinical Data

- Imugene Limited (ASX: IMU) (Imugene or the Company) has received firm commitments to raise approximately $11.12 million (before costs) via a placement of approximately 117.1 million new fully paid ordinary shares (New Shares) to sophisticated, professional and institutional investors at an issue price of $0.095 per New Share (Offer Price)
- The Placement is expected to raise approximately $11.12 million (before costs) providing funding into CY2027
- Placement participants include a global, commercial-stage biopharmaceutical company, which subscribed for approximately 14% of the Placement, subject to shareholder approval
- The Placement has attracted strong support from existing and new institutional investors, including long-only global investors
- Proceeds of the Offer will be used to advance the Company's lead asset, azer-cel, through key clinical and regulatory milestones, and for general working capital purposes
- The Offer follows complete responses (CRs) in the first two evaluable patients in the concurrent BTKi + azer-cel combination cohort (Cohort 3), a Follicular Lymphoma (FL) patient and a Mantle Cell Lymphoma (MCL) patient
- These early results strengthen the clinical rationale for azer-cel in patients whose disease has progressed following BTKi therapy, a therapeutic market worth more than US$12 billion annually
- With further patient readouts expected from the BTKi combination and CAR-T naïve cohorts over the next 6 to 12 months, including presentations at major scientific conferences in CY2026, Imugene is entering an important period for business development, supporting ongoing potential collaboration discussions for azer-cel

*Not for release to US wire services or distribution in the United States*

**SYDNEY, Australia, 7 July 2026:** Imugene Limited ("**Imugene**", the "**Company**", "**ASX:IMU**") , a clinical-stage immuno-oncology company, is pleased to announce it has received firm commitments from sophisticated, professional and institutional investors for a two-tranche placement to raise approximately $11.12 million (before costs) ( the "**Placement**") through the issue of approximately 117.1 million new fully paid ordinary shares ("**New Shares**") at an issue price of $0.095 per New Share ("**Offer Price**"). The Placement was strongly supported by new and existing institutional investors, including long-only global investors and a global pharmaceutical company.

The Placement includes a placement to Directors of Imugene to raise approximately $0.12m (before costs) through the issuance of ~1.3m New Shares ("**Directors Placement**") subject to shareholder approval.

Managing Director and Chief Executive Officer, Leslie Chong said: "The first two evaluable patients in our concurrent BTKi combination cohort have both achieved complete responses, providing a strong early clinical signal for azer-cel in a therapeutic class worth more than US$12 billion annually. This Placement funds a series of important clinical data readouts over the next 6–12 months, including presentations at ASH and ASCO, while supporting our ongoing business development activities and continued discussions with potential pharmaceutical partners. We thank our shareholders, new investors and Directors for their ongoing support as we advance azer-cel towards a registrational pathway"

**About the Placement**

Under the terms of the Placement, the Company has secured firm commitments for approximately $11.1 million and proposes to issue approximately 117.1 million New Shares to Placement participants at an issue price of $0.095 per New Share, representing a discount of:

- 17.7% to the 30-day VWAP of $0.115 up to and including Thursday, 2 July 2026; and
- 29.6% to the last closing price of $0.135 on Thursday, 2 July 2026.

Shares under the Placement will be issued as follows:

For personal use only

- Tranche 1 Placement to raise A$7.0 million (before costs) through the issuance of approximately 73.7 million New Shares ("**Tranche 1 Placement**") pursuant to the Company's placement capacity under Listing Rules 7.1 and 7.1A; and
- Tranche 2 Placement to certain investors, including Directors of Imugene to raise $4.1m (before costs) through the issuance of 43.4m New Shares, with any shares in excess of the company's placement capacity under Listing Rules 7.1 and 7.1A ("**Tranche 2 Placement**") and the issue of shares under the Directors Placement subject to shareholder approval at the EGM

Placement participants include an international, commercial-stage biopharmaceutical company, which subscribed for approximately 14% of the Placement, subject to shareholder approval.

Bell Potter Securities Limited acted as Lead Manager and Bookrunner to the Placement.

**Use of Funds**

Proceeds of the Offer will primarily be used to fund the continued development of azer-cel, including the expansion of Cohort 2 (CAR-T naïve indications) and Cohort 3 (BTKi combination) of the ongoing Phase 1b trial, associated regulatory engagement and manufacturing scale-up activities, together with general working capital.

**Recent Clinical Progress**

The Offer follows recent positive clinical updates from the concurrent BTKi combination cohort (Cohort 3) of the Company's Phase 1b azer-cel study:

- On 30 June 2026, Imugene announced the first complete response in the concurrent BTKi cohort, with a BTKi-refractory Follicular Lymphoma (FL) patient achieving a complete response at Day 28.
- On 1 July 2026, Imugene announced a second complete response in the concurrent BTKi cohort, with the first Mantle Cell Lymphoma (MCL) patient treated in the study achieving a complete response, taking the response rate to 2/2 evaluable patients.

For personal use only

BTK inhibitors are an established standard of care across multiple B-cell malignancies (Blood cancers). Published clinical studies evaluating BTK inhibitors in combination with autologous CD19 CAR-T therapies have reported encouraging efficacy, supporting the biological rationale for combining BTK inhibition with CAR-T therapy. Imugene's early but encouraging results provide the first clinical evidence supporting this approach with azer-cel, an allogeneic CAR-T therapy.

With additional patient readouts expected across the BTKi and CAR-T naïve cohorts over the next 6-12 months, and potential data presentations anticipated at ASH 2026 and ASCO 2027, the Company considers it is entering a period conducive to advancing partnering and out-licensing discussions for azer-cel.

**Key Dates**

| Event | Date |
|---|---|
| Trading halt | Friday, 3 July 2026 |
| Bookbuild | Friday, 3 July 2026 |
| Announcement of Offer and trading halt lifted | Tuesday, 7 July 2026 |
| Settlement of New Shares issued under Tranche 1 of the Placement | Friday, 10 July 2026 |
| Allotment of New Shares issued under Tranche 1 of the Placement | Monday, 13 July 2026 |
| EGM to approve issue of New Shares under Tranche 2 of the Placement and the Directors Placement | Expected on or around Tuesday, 18 August 2026 |
| Settlement of New Shares issued under Tranche 2 of the Placement and Directors Placement | Expected on or around Friday, 21 August 2026 |
| Allotment of New Shares issued under Tranche 2 of the Placement and Directors Placement | Expected on or around Monday, 24 August 2026 |

For personal use only

*The Company reserves the right to amend the above timetable, at its discretion, including for the purposes of any Australian Securities and Investments Commission (ASIC) and ASX requirements.*

For more information please contact:

**Leslie Chong**
**Managing Director and Chief Executive Officer**
info@imugene.com

**General Investor Enquiries**
shareholderenquiries@imugene.com

**Media Enquiries**
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

**About Imugene (ASX:IMU)**

Imugene is a clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*

For personal use only